Ginkgo Bioworks Holdings, INC Form 4 insider transactions

Barry Canton, a 10% owner of Ginkgo Bioworks Holdings, Inc., reported multiple transactions in common stock on July 28, 2026.

Reshma P. Shetty, See remarks, a Director and 10% owner of Ginkgo Bioworks Holdings, Inc., reported multiple transactions in common stock on July 28, 2026.

Jason R Kelly, See remarks and a Director of Ginkgo Bioworks Holdings, Inc., reported multiple transactions in common stock on July 28, 2026.

Steven P. Coen, See remarks of Ginkgo Bioworks Holdings, Inc., sold 752 shares of common stock on July 16, 2026 for $7.90 per share.

Ginkgo Bioworks Director Christian O. Henry received a grant of 25,000 Restricted Stock Units as part of the company's non-employee director compensation program.

Ginkgo Bioworks Holdings, Inc. reports that Director Ross Fubini was granted 25,000 Restricted Stock Units (RSUs) on June 11, 2026, with vesting conditions tied to continued service.

Ginkgo Bioworks Holdings, Inc. Director Kosuri Sri was granted 25,000 restricted stock units under the company's Non-Employee Director Compensation Program.

Ginkgo Bioworks Holdings, Inc. Director Harry Sloan was granted 25,000 restricted stock units under the company's non-employee director compensation program.

Steven P. Coen, CFO of Ginkgo Bioworks Holdings, Inc., reported transactions involving Class A Common Stock and Restricted Stock Units.

Ginkgo Bioworks CFO Steven P. Coen sold shares to satisfy tax withholding obligations following the vesting of restricted stock units.

Ginkgo Bioworks Holdings, Inc. CFO Steven P. Coen sold shares to cover tax obligations related to vested performance-based restricted stock units.

Barry Canton, a director at Ginkgo Bioworks Holdings, Inc., reported transactions involving Class A Common Stock and performance-based restricted stock units.

Reshma P. Shetty, a Director and 10% owner of Ginkgo Bioworks Holdings, Inc., reported a sale of 124,727 shares of Class A Common Stock on April 10, 2026, to cover tax withholding obligations related to vested performance-based restricted stock units.

Reshma Shetty, a Director and 10% owner of Ginkgo Bioworks Holdings, Inc., reported the sale of Class A Common Stock by her spouse to cover tax obligations related to vested performance-based restricted stock units.

Barry Canton, a director at Ginkgo Bioworks Holdings, Inc., reported transactions involving the sale of Class A Common Stock to cover tax withholding obligations related to vested performance-based restricted stock units.

Ginkgo Bioworks Holdings, Inc. reports insider Jason R. Kelly's sale of Class A Common Stock to cover tax obligations related to vesting performance-based restricted stock units.

Ginkgo Bioworks' CFO, Steven P. Coen, reported the acquisition of Class A Common Stock through RSU vesting and a subsequent sale to cover tax obligations.

Ginkgo Bioworks Holdings, Inc. CFO Steven P. Coen reported the vesting of restricted stock units and a subsequent sale of shares to cover tax withholding obligations.

Ginkgo Bioworks Holdings, Inc. CFO Steven P. Coen reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Ginkgo Bioworks' Chief Financial Officer, Steven P. Coen, reported a planned sale of 5,609 shares of Class A Common Stock for $15 per share, effective October 1, 2025, under a Rule 10b5-1 plan.

Ginkgo Bioworks Holdings, Inc. Director Christian O. Henry sold 20,000 shares of Class A Common Stock over two days in early September 2025.

Ginkgo Bioworks' Chief Financial Officer, Steven P. Coen, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Ginkgo Bioworks Holdings, Inc.'s Chief Financial Officer, Steven P. Coen, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax withholding obligations.

Ginkgo Bioworks Holdings, Inc. Director Myrtle S. Potter acquired 10,822 shares of Class A Common Stock on June 11, 2025, through the vesting of previously granted Restricted Stock Units.

Ginkgo Bioworks Holdings, Inc. Director Kathy Hopinkah Hannan converted 10,822 restricted stock units into Class A Common Stock on June 11, 2025, as part of her compensation program.

Ginkgo Bioworks Holdings, Inc. Director Harry Sloan reported the vesting of restricted stock units and the grant of new stock options, increasing his direct ownership of Class A Common Stock.

Ginkgo Bioworks Holdings, Inc. Director Shyam Sankar reported the vesting of restricted stock units and the grant of new stock options, increasing his beneficial ownership in the company.

Ginkgo Bioworks Holdings, Inc. Director Sri Kosuri has reported the vesting of 24,067 restricted stock units and the acquisition of 34,375 new stock options, as disclosed in a recent SEC Form 4 filing.

Ginkgo Bioworks Holdings, Inc. Director Christian O. Henry reported the conversion of 10,822 restricted stock units into Class A shares and the grant of 34,375 new stock options.

Ginkgo Bioworks Holdings, Inc. Director Ross Fubini has reported the vesting of 10,822 restricted stock units and the grant of 34,375 new stock options as part of his non-employee director compensation.